• In July 2023, Beckman Coulter announced a strategic collaboration with Fujirebio to expand access to blood‑based Alzheimer’s disease assays, aiming to improve early detection capabilities in neurology diagnostics.

• In December 2024, researchers unveiled a deep learning-enhanced chemiluminescence vertical flow assay for ultra‑sensitive cardiac troponin I testing at point‑of‑care, detecting myocardial injury in just 25 minutes with lab‑grade precision.

In this report, the In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Technology, Product, Application, End Users and Geography.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by Technology

The In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Technology into Clinical Chemistry, Immunoassay, Microbiology, Hematology, Molecular Diagnostics, Coagulation and Others.

Clinical Chemistry

Clinical chemistry holds a significant position in the IVD market, accounting for approximately 17% of the global share in 2024. This segment focuses on the analysis of biochemical components in bodily fluids, such as blood and urine, to diagnose and monitor various diseases. Advancements in automation and the development of point-of-care testing solutions have enhanced the efficiency and accuracy of clinical chemistry tests. The growing demand for real-time diagnostics in critical care settings and the expansion of personalized medicine are key drivers of this segment's growth.

Immunoassay

Immunoassays dominate the IVD market, capturing the largest share at approximately 26% in 2024. These assays are essential for detecting specific proteins, hormones, and antibodies, playing a crucial role in diagnosing infections, cancers, and chronic conditions. The segment's growth is propelled by the increasing prevalence of chronic and infectious diseases, along with the rising demand for early and accurate diagnosis. Innovations in immunoassay technologies, such as chemiluminescence immunoassays (CLIAs), have further enhanced their sensitivity and specificity.

Microbiology

The microbiology segment accounts for approximately 9% of the IVD market in 2024. It focuses on identifying pathogens responsible for infectious diseases through culture-based or molecular methods. The segment's growth is driven by the increasing incidence of infectious diseases, antibiotic resistance, and the need for rapid pathogen identification. Advancements in automation and the development of rapid diagnostic tests have significantly improved the efficiency and accuracy of microbiological analyses.

Hematology

Hematology represents about 5% of the IVD market in 2024, concentrating on the analysis of blood samples to diagnose conditions like anemia, infections, and blood cancers. The segment benefits from technological advancements in hematology analyzers, enabling high-throughput testing and enhanced cell counting accuracy. The integration of digital solutions for remote monitoring and the rising incidence of blood disorders contribute to the segment's growth.

Molecular Diagnostics

Molecular diagnostics hold a substantial share of the IVD market, accounting for approximately 21% in 2024. This segment utilizes nucleic acid testing to detect genetic variations and infectious agents, playing a pivotal role in personalized medicine and targeted therapies. The adoption of next-generation sequencing (NGS) and the development of rapid PCR-based tests have revolutionized disease detection and monitoring. The increasing prevalence of genetic disorders and the demand for precise diagnostic tools are key drivers of this segment.

Coagulation

Coagulation testing comprises over 8% of the IVD market in 2024, focusing on analyzing blood clotting mechanisms to diagnose bleeding disorders and monitor anticoagulant therapies. The segment's growth is fueled by the aging population, rising incidence of cardiovascular diseases, and the need for accurate monitoring of coagulation disorders. Advancements in automation and the development of point-of-care devices have enhanced the accessibility and efficiency of coagulation testing.

Others

The 'Others' category encompasses emerging technologies like flow cytometry, cytogenetics, and mass spectrometry, representing approximately 14% of the IVD market in 2024. These technologies offer advanced analytical capabilities for specialized diagnostic applications, including allergy testing, reproductive health, and neurology. The segment's growth is driven by increasing awareness and diagnosis rates, advancements in analytical techniques, and the demand for specialized diagnostic solutions in niche medical fields.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by Product

The In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Product into Instruments and Consumables/Reagents.

Instruments

The instruments segment plays a pivotal role in the IVD market for cardiology and neurology, encompassing devices such as analyzers, imaging systems, and automated platforms that facilitate diagnostic procedures. In 2023, this segment contributed approximately 34.12% to the global market revenue. The demand for advanced diagnostic equipment is driven by the need for accurate and efficient testing methodologies, especially in clinical laboratories and hospital settings. Technological advancements and the integration of automation are further propelling the growth of this segment.

Reagents & Consumables

Accounting for a substantial 65.88% of the global market revenue in 2023, the reagents and consumables segment dominates the IVD landscape in cardiology and neurology. This category includes essential components like fluorescent tags, antibodies, protein biomarkers, and PCR reagents that are integral to various diagnostic assays. The high consumption rate of these products, coupled with ongoing research and development efforts to introduce novel biomarker kits, underscores their critical role in facilitating accurate and timely diagnoses. The segment's growth is further bolstered by the increasing prevalence of cardiovascular and neurological disorders, necessitating frequent and reliable testing solutions.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by Application

The In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Application into Cardiology and Neurology.

Cardiology

The cardiology segment commands a substantial share of the IVD market for cardiology and neurology, accounting for about 58% of the global revenue in 2023. This growth is fueled by the rising incidence of cardiovascular diseases (CVDs), such as coronary artery disease, arrhythmias, and heart failure. The growing focus on early detection and accurate monitoring has increased the demand for advanced diagnostic tools, including biomarkers and imaging techniques. Continuous advancements in diagnostic technologies and the integration of AI-driven solutions are poised to further expand this segment.

Neurology

The neurology segment has gained traction in the IVD market, representing approximately 42% of the global share in 2023. This segment’s growth is propelled by the rising prevalence of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and epilepsy. The increasing need for precise and early diagnosis has spurred innovations in molecular diagnostics and the development of novel assays. Progress in genomics and proteomics is enhancing diagnostic accuracy, while investments in research and development are driving sustained growth.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by End Users

The In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by End Users into Academics, Hospitals & Laboratories, Pharmaceutical & Biotechnology and Others.

Academics

Academic institutions are instrumental in propelling the IVD landscape forward, particularly in cardiology and neurology. Their research initiatives lead to groundbreaking diagnostic innovations, enhancing early detection and treatment strategies. Collaborations between academia and industry stakeholders further accelerate the translation of research findings into practical diagnostic applications.

Hospitals & Laboratories

Dominating the IVD market, hospitals and laboratories are central to the deployment of diagnostic technologies. With a commanding share of approximately 60% in 2023, these facilities prioritize the integration of cutting-edge diagnostic tools to improve patient outcomes. The emphasis on precision medicine and the management of complex cardiovascular and neurological disorders underscores the critical role of this segment.

Pharmaceutical & Biotechnology

The pharmaceutical and biotechnology sector is a significant contributor to the IVD market, leveraging diagnostic tools for drug discovery and development. Holding an estimated 25% market share in 2023, this segment's growth is fueled by the surge in personalized medicine and the necessity for companion diagnostics. The continuous pursuit of targeted therapies amplifies the demand for specialized diagnostic solutions.

Others

Encompassing diagnostic clinics, point-of-care centers, and home healthcare services, the 'Others' segment plays a pivotal role in expanding the reach of IVD technologies. Accounting for about 15% of the market in 2023, this segment's growth is driven by the increasing need for accessible and rapid diagnostic solutions, especially in remote and resource-limited settings.

In Vitro Diagnostics for Cardiology and Neurology Market, Segmentation by Geography

In this report, the In Vitro Diagnostics for Cardiology and Neurology Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

In Vitro Diagnostics for Cardiology and Neurology Market Share (%), by Geographical Region

North America

North America dominates the global IVD market for cardiology and neurology, holding approximately 42.28% of the market share in 2023. This leadership is driven by a high prevalence of cardiovascular and neurological disorders, robust healthcare infrastructure, and significant investments in research and development. The region's focus on early diagnosis and personalized treatment approaches further accelerates market growth.

Europe

Europe maintains a strong presence in the IVD market, with a notable share of 28.81% in 2022. The market benefits from increased research funding, a high burden of cardiovascular diseases, and the presence of leading diagnostic companies. Countries such as the UK, France, and Germany are at the forefront, owing to their advanced healthcare systems and emphasis on early disease detection.

Asia Pacific

Asia Pacific is poised for significant growth in the IVD sector, expected to dominate the majority revenue share by 2037. Factors contributing to this surge include escalating healthcare investments, rising awareness about early diagnosis, and a growing patient population. The region's commitment to enhancing diagnostic capabilities positions it as a key player in the global market.

Middle East and Africa

The MEA region accounted for 3.6% of the global IVD market in 2022, with projections indicating a CAGR of 8.8% from 2023 to 2030. This growth is propelled by an increasing incidence of cardiovascular and neurological diseases and ongoing improvements in healthcare infrastructure. The UAE is anticipated to experience the highest growth rate within the region.

Latin America

Latin America emerges as the fastest-growing region in the IVD market, with expectations to reach USD 1,508.3 million by 2030. The region's growth is driven by technological advancements, heightened awareness of diagnostic tools, and a rising prevalence of target diseases. Brazil, in particular, is projected to play a significant role in this expansion.

This report provides an in depth analysis of various factors that impact the dynamics of In Vitro Diagnostics for Cardiology and Neurology Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Technological advancements boost
• Increasing chronic diseases prevalence

• Growing awareness campaigns - The increasing number of public health awareness campaigns is playing a pivotal role in boosting the adoption of in vitro diagnostics (IVD) for cardiology and neurology. Governments, non-profit organizations, and private healthcare providers are actively promoting the importance of early diagnosis of cardiovascular and neurological disorders. These campaigns are educating the general population about risk factors, symptoms, and the availability of advanced diagnostic tools.

  This widespread outreach is leading to higher patient participation in preventive health check-ups and increasing demand for accurate laboratory testing. Public engagement in screening programs is helping identify conditions like stroke, Alzheimer’s disease, and ischemic heart disease at earlier stages, allowing for better treatment outcomes and improved quality of life.

  Moreover, targeted awareness efforts in developing countries are helping to bridge the diagnostic access gap. In vitro diagnostics are now being integrated into primary care settings where educational outreach has successfully raised public concern about chronic illness detection. As patient awareness increases, so does demand for reliable biomarker testing and advanced point-of-care diagnostics.

  With global health authorities emphasizing non-communicable disease management, such campaigns are also influencing policy decisions and reimbursement support. The result is a reinforcing loop where greater awareness leads to higher diagnostic testing rates, which in turn drives further investment in IVD for cardiology and neurology.

Restraints

• Stringent regulatory requirements
• Limited reimbursement policies

• Lack of skilled professionals - One of the major challenges hindering the growth of the in vitro diagnostics market for cardiology and neurology is the lack of skilled professionals. Advanced diagnostic procedures require well-trained personnel who can handle sensitive biomarker assays, analyze test results accurately, and ensure the quality control of laboratory processes. In many regions, particularly in low- and middle-income countries, there is a shortage of such qualified experts.

  This shortage leads to delays in test processing, increased chances of diagnostic errors, and decreased confidence among clinicians relying on these results. Without a strong workforce of trained technicians and diagnostic specialists, the effectiveness of in vitro diagnostics in critical areas such as neurological screening and cardiac biomarker testing becomes compromised.

  The issue is compounded by the complexity of the instruments and tests used. As diagnostic platforms become more sophisticated—incorporating molecular diagnostics and automated systems—they require even greater expertise. Unfortunately, the pace of technological advancement often outstrips the development of educational programs and hands-on training opportunities.

  Addressing this gap will require investment in training programs, capacity-building initiatives, and collaboration with academic institutions. Until such measures are widely implemented, the growth potential of IVD for cardiology and neurology will remain partly constrained by this human resource bottleneck.

Opportunities

• Personalized medicine adoption
• Point-of-care testing demand

• AI and machine learning utilization - The integration of artificial intelligence (AI) and machine learning (ML) in in vitro diagnostics presents a transformative opportunity for cardiology and neurology. These technologies enable faster, more accurate interpretation of complex data, improving the sensitivity and specificity of diagnostic algorithms. AI-driven tools can analyze large datasets, identify subtle patterns, and assist clinicians in making more precise decisions for early disease detection.

  AI is particularly useful in interpreting biomarkers for conditions like Alzheimer’s, Parkinson’s, and cardiac arrhythmias. Machine learning models trained on historical diagnostic data can provide predictive insights into disease progression, allowing healthcare providers to implement proactive treatment plans. These tools are not only enhancing diagnostic capabilities but also reducing the burden on overworked lab professionals.

  The adoption of AI also supports the automation of laboratory processes, improving workflow efficiency and reducing human error. Automated result interpretation, test prioritization, and sample tracking are just a few areas where machine learning can improve overall productivity and turnaround time. This is particularly beneficial in high-volume settings such as hospitals and diagnostic chains.

  As AI and ML technologies become more accessible and cost-effective, they are expected to be embedded in a wide range of diagnostic platforms. Their integration into IVD devices offers the potential to revolutionize patient care, enable more widespread screening, and elevate the role of diagnostics in precision medicine for cardiology and neurology.

Key players in In Vitro Diagnostics for Cardiology and Neurology Market include:

• Quest Diagnostics
• Alere Inc
• GE Healthcare
• Thermo Fisher Scientific
• Agilent Technologies
• Bio-Rad Laboratories
• Eurofins Scientific
• Covance
• Promega Corporation
• Merck KGaA

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis